Health & Safety Issues in Orlando | Orlando Legal Examiner

FDA: Bausch & Lomb Failed to Promptly Notify

The FDA said yesterday that ReNu maker Bausch & Lomb failed to promptly report 35 cases of the fusarium keratitis infection. The failure to inform the FDA within a 30 day time period is part of a larger list of 20 violations the FDA listed after inspecting the Greensville, SC plant.

By The Legal Examiner

/ 17 May 2006

More News on Bausch & Lomb

I was quoted in today’s Boston Globe as a result of Bausch & Lomb’s decision to halt permanently the worldwide sales of its ReNu with MoistureLoc. As the paper stated, I think the decision confirms what we’ve suspected all along, namely, that the problem lies in the solution itself.

By The Legal Examiner

/ 16 May 2006

Bausch & Lomb Hasn't Removed ReNu with MultiPlus

In spite of a sharp increase in fungal infections among users of ReNu with MultiPlus, Bausch & Lomb has not removed the eye contact solution product from store shelves. US health officials have now confirmed more than 120 cases of a potentially blinding eye infection that may be related to contact l

By The Legal Examiner

/ 15 May 2006

Vioxx Risks Continue Even After Its Use is Discontinued

A new Merck & Co. study reveals that risk for heart attacks and strokes continues even when its use is discontinued. This risk continues for a year after use. In spite of the new study, Merck says it won’t change its litigation strategy. Oh well, why be confused with the facts.

By The Legal Examiner

/ 12 May 2006

Link Between Fusarium Fungus and Bausch & Lomb Grows Stronger According to Latest CDC Data

According to the latest CDC data, the link between ReNu with Moisture Loc and the rare but dangerous fusarium keratitis fungus continues to grow sharply. The link between another ReNu product, ReNu Moisture Plus, grew, but more modestly. Of the 98 confirmed Fusarium keratitis cases for which the CDC

By The Legal Examiner

/ 10 May 2006

Fosamax-More Harm than Cure

Fosamax, manufactured by Vioxx maker Merck & Co., is an osteoporosis drug highly touted by its manufacturer. The drug garnered $3.2 billion in 2005 sales but is now linked to osteonecrosis whereby users of Fosamax experience a rotting and death of the jaw bone. Fosamax, which contains the active com

By The Legal Examiner

/ 9 May 2006

Source of Fusarium Keratitis Fungus Still a Mystery

According to an article in the NY Times, a researcher hired by Bausch & Lomb has published a report indicating that the infection is not coming from the eye contact solution. The FDA and CDC have not commented directly on his findings. FDA officials declined to comment yesterday on Mr. Geiser’s asse

By The Legal Examiner

/ 7 May 2006

5 More Suspected Cases of Fungal Eye Infection in Tennessee

With reports of the fusarium keratitis fungus appearing in Europe, the number of cases in Tennessee continues to mount. I haven’t read a good explanation for this but the number of eye fungus infections associated with Bausch & Lomb’s ReNu products is quite high in comparison with other states.

By The Legal Examiner

/ 5 May 2006

Bausch & Lomb Fungus Enters Europe

New cases of the fusarium keratitis fungus have been confirmed in Europe. The cases represent the first time the company has acknowledged European incidents of the infection, which has struck Bausch solution users in Asia and the U.S. The outbreak has led the company to halt shipments of one of its

By The Legal Examiner

/ 4 May 2006

Sites Set on Bausch & Lomb

As the days pass, the news continues to get worse for Bausch & Lomb. Initially, the company asked consumers to stop using one of their products, ReNu with MoistureLoc. In the intervening weeks, company execs tried to intimate that if there was a problem at all, it was restricted to the one product.

By The Legal Examiner

/ 4 May 2006

Bristol Myers Squibb to Stop Selling Tequin

In a conference call with investors, Bristol Myers Squibb has announced that it will no longer sell Tequin although it stopped short of saying that the product will be removed from store shelves. The decision comes on the heels of Public Citizen’s call to ban the drug.

By The Legal Examiner

/ 3 May 2006

Why Bausch & Lomb Withdrew ReNu from the Market

The relationship between the recent outbreak of fusarium keratitis and Bausch & Lomb’s ReNu eye contact solution is becoming clearer as the CDC and the FDA continues its investigation. According to an article in Reuters, “The 57 percent share of cases preliminarily reported for the company’s Moistur

By The Legal Examiner

/ 3 May 2006